149 related articles for article (PubMed ID: 37595560)
1. Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB).
Epstein AL; Haag-Molkenteller C
Cell; 2023 Aug; 186(17):3523-3523.e1. PubMed ID: 37595560
[TBL] [Abstract][Full Text] [Related]
2. Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa.
Paller AS; Guide SV; Ayala D; Gonzalez ME; Lucky AW; Bagci IS; Marinkovich MP
J Dermatolog Treat; 2024 Dec; 35(1):2350232. PubMed ID: 38724041
[TBL] [Abstract][Full Text] [Related]
3. Beremagene Geperpavec: First Approval.
Dhillon S
Drugs; 2023 Aug; 83(12):1131-1135. PubMed ID: 37432558
[TBL] [Abstract][Full Text] [Related]
4. Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa.
Raymakers AJN; Kesselheim AS; Mostaghimi A; Feldman WB
JAMA Dermatol; 2024 Mar; 160(3):297-302. PubMed ID: 38294784
[TBL] [Abstract][Full Text] [Related]
5. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
Guide SV; Gonzalez ME; Bağcı IS; Agostini B; Chen H; Feeney G; Steimer M; Kapadia B; Sridhar K; Quesada Sanchez L; Gonzalez F; Van Ligten M; Parry TJ; Chitra S; Kammerman LA; Krishnan S; Marinkovich MP
N Engl J Med; 2022 Dec; 387(24):2211-2219. PubMed ID: 36516090
[TBL] [Abstract][Full Text] [Related]
6. Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critically appraised research paper.
Doolan BJ; McGrath JA; Mellerio JE
Br J Dermatol; 2024 Feb; 190(3):340-342. PubMed ID: 37936299
[No Abstract] [Full Text] [Related]
7. Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa.
Tovar Vetencourt A; Sayed-Ahmed I; Gomez J; Chen H; Agostini B; Carroll K; Parry T; Krishnan S; Sabater AL
N Engl J Med; 2024 Feb; 390(6):530-535. PubMed ID: 38324486
[TBL] [Abstract][Full Text] [Related]
8. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.
Gurevich I; Agarwal P; Zhang P; Dolorito JA; Oliver S; Liu H; Reitze N; Sarma N; Bagci IS; Sridhar K; Kakarla V; Yenamandra VK; O'Malley M; Prisco M; Tufa SF; Keene DR; South AP; Krishnan SM; Marinkovich MP
Nat Med; 2022 Apr; 28(4):780-788. PubMed ID: 35347281
[TBL] [Abstract][Full Text] [Related]
9. Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa.
Khan A; Riaz R; Ashraf S; Akilimali A
Ann Med Surg (Lond); 2023 Dec; 85(12):6298-6301. PubMed ID: 38098548
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of a recombinant truncated type VII collagen "minigene". Implication for gene therapy of dystrophic epidermolysis bullosa.
Chen M; O'Toole EA; Muellenhoff M; Medina E; Kasahara N; Woodley DT
J Biol Chem; 2000 Aug; 275(32):24429-35. PubMed ID: 10821839
[TBL] [Abstract][Full Text] [Related]
11. Fibroblasts as target cells for DEB gene therapy.
Chen M; Woodley DT
J Invest Dermatol; 2006 Apr; 126(4):708-10. PubMed ID: 16541096
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for recessive dystrophic epidermolysis bullosa.
Titeux M; Pendaries V; Hovnanian A
Dermatol Clin; 2010 Apr; 28(2):361-6, xii. PubMed ID: 20447504
[TBL] [Abstract][Full Text] [Related]
13. Overcoming obstacles for gene therapy for recessive dystrophic epidermolysis bullosa.
Lanuti EL; Wikramanayake TC; Kirsner RS
J Invest Dermatol; 2011 Jan; 131(1):5. PubMed ID: 21157419
[No Abstract] [Full Text] [Related]
14. A Case Report of an Infant with Autosomal Recessive Dystrophic Epidermolysis Bullosa: COL7A1 Gene Mutations at C2005T and G7922A.
Liu J; Wang L
Acta Dermatovenerol Croat; 2021 Dec; 29(3):164-166. PubMed ID: 34990346
[TBL] [Abstract][Full Text] [Related]
15. Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa.
Vanden Oever M; Twaroski K; Osborn MJ; Wagner JE; Tolar J
Pediatr Res; 2018 Jan; 83(1-2):318-324. PubMed ID: 29593249
[TBL] [Abstract][Full Text] [Related]
16. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
Bornert O; Hogervorst M; Nauroy P; Bischof J; Swildens J; Athanasiou I; Tufa SF; Keene DR; Kiritsi D; Hainzl S; Murauer EM; Marinkovich MP; Platenburg G; Hausser I; Wally V; Ritsema T; Koller U; Haisma EM; Nyström A
J Invest Dermatol; 2021 Apr; 141(4):883-893.e6. PubMed ID: 32946877
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.
Cutlar L; Greiser U; Wang W
Exp Dermatol; 2014 Jan; 23(1):1-6. PubMed ID: 24107073
[TBL] [Abstract][Full Text] [Related]
18. Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Eichstadt S; Barriga M; Ponakala A; Teng C; Nguyen NT; Siprashvili Z; Nazaroff J; Gorell ES; Chiou AS; Taylor L; Khuu P; Keene DR; Rieger K; Khosla RK; Furukawa LK; Lorenz HP; Marinkovich MP; Tang JY
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31578311
[TBL] [Abstract][Full Text] [Related]
19. Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa.
Dang N; Murrell DF
Exp Dermatol; 2008 Jul; 17(7):553-68. PubMed ID: 18558993
[TBL] [Abstract][Full Text] [Related]
20. siRNA-mediated allele-specific inhibition of mutant type VII collagen in dominant dystrophic epidermolysis bullosa.
Pendaries V; Gasc G; Titeux M; Tonasso L; Mejía JE; Hovnanian A
J Invest Dermatol; 2012 Jun; 132(6):1741-3. PubMed ID: 22336946
[No Abstract] [Full Text] [Related]
[Next] [New Search]
